Novel Findings on Activation of PD1/PD-L1 that Contributes to Cancer Development and Metastasis

【作者】 谢丽叶付杰军卢奕张健

【Author】 XIE Liye;FU Jiejun;LU Yi;ZHANG Jian;Center for Translational Medicine,Guangxi Medical University,Key Laboratory of Longevity and Ageing-related Diseases,Ministry of Education;School of Medicine,Southern University of Science and Technology;Department of Urology,University of Pittsburgh School of Medicine;

【机构】 广西医科大学转化医学研究中心,长寿与老年相关疾病教育部重点实验室南方科技大学医学院美国匹兹堡大学医学院泌尿系

【摘要】 程序性死亡受体1(PD1)和程序性死亡配体1(PD-L1)是重要的负性免疫调节因子。T细胞表面PD1受体与肿瘤细胞表面表达的PD-L1配体结合,向细胞内传递调控信号,抑制T细胞活化与增殖,从而介导肿瘤细胞的免疫逃逸及对常规放化疗的抵抗。近年来,针对PD1/PD-L1的单克隆抗体靶向药物在非小细胞肺癌和黑色素瘤等实体肿瘤治疗中均取得了较好的疗效,显著改善了部分肿瘤患者的临床进展和不良预后。本文综述了PD1/PD-L1在肿瘤发生、发展和转移中的重要作用以及PD1/PD-L1抗体应用于肿瘤免疫治疗中的最新进展。

【Abstract】 Programmed cell death protein-1(PD1) and programmed cell death protein-1 ligand 1(PD-L1) act as important negative immune regulators. Combining PD1 receptors on T cells with their corresponding ligands PD-L1 on tumor cells can inhibit T cell activation and lead to tumor cell immune escape and resistance to conventional chemotherapy. In recent years, the drugs targeting PD1/PD-L1 monoclonal antibodies have achieved promising effects in various tumor types including non-small cell lung carcinoma and melanoma. They also dramatically improved poor prognosis and overall survival of some tumor patients. In this review, we will summerize the novel findings on the activation of PD1/PD-L1 in tumor occurrence, development and metastasis, as well as the updated clinical progress of using anti-PD1 or anti-PD-L1 in tumor immunotherapy.

【关键词】 PD1; PD-L1; 肿瘤发展; 转移; 免疫治疗;

【Key words】 PD1; PD-L1; Cancer development; Metastasis; Immunotherapy;


【基金】 国家自然科学基金重点项目(81130046);国家自然科学基金面上项目(81272415,81171993)

  • 【下载频次】1456